Monika Hegi

Monika Hegi established MGMT promoter methylation as the most important predictive biomarker in glioblastoma, demonstrating in the landmark EORTC/NCIC trial that patients with methylated MGMT promoters derive substantial survival benefit from temozolomide chemotherapy while those with unmethylated promoters show minimal benefit. Her work translated a molecular epigenetic marker into routine clinical practice, fundamentally changing treatment decision-making in neuro-oncology. She has contributed to broader methylation-based classification systems for brain tumors and continues to develop epigenetic biomarkers for precision neuro-oncology therapeutic stratification.